➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Mallinckrodt
Merck
Dow
Moodys

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VISTIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Vistide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000135 ↗ Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT) Completed Johns Hopkins Bloomberg School of Public Health Phase 2/Phase 3 1995-09-01 To evaluate the efficacy and safety of a human anti-CMV monoclonal antibody, MSL-109, as adjunct therapy for controlling CMV retinitis.
NCT00000142 ↗ Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed Baylor College of Medicine Phase 2/Phase 3 1994-04-01 To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously known as HPMPC) for the treatment of retinitis.
NCT00000142 ↗ Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed Icahn School of Medicine at Mount Sinai Phase 2/Phase 3 1994-04-01 To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously known as HPMPC) for the treatment of retinitis.
NCT00000142 ↗ Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed Johns Hopkins University Phase 2/Phase 3 1994-04-01 To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously known as HPMPC) for the treatment of retinitis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vistide

Condition Name

Condition Name for Vistide
Intervention Trials
HIV Infections 4
Cytomegalovirus Retinitis 3
Cervical Cancer 1
Prevention of Hair Growth 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vistide
Intervention Trials
Retinitis 4
HIV Infections 4
Cytomegalovirus Retinitis 4
Uterine Cervical Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vistide

Trials by Country

Trials by Country for Vistide
Location Trials
United States 13
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vistide
Location Trials
Pennsylvania 1
Texas 1
North Carolina 1
New York 1
New Jersey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vistide

Clinical Trial Phase

Clinical Trial Phase for Vistide
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 2
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vistide
Clinical Trial Phase Trials
Completed 5
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vistide

Sponsor Name

Sponsor Name for Vistide
Sponsor Trials
Johns Hopkins Bloomberg School of Public Health 3
New Jersey Medical School 1
University of Miami 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vistide
Sponsor Trials
Other 19
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Boehringer Ingelheim
McKinsey
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.